114 related articles for article (PubMed ID: 18203000)
1. High dose therapy for light chain amyloidosis: can we reduce treatment related mortality further?
Dimopoulos M; Kastritis E
Leuk Lymphoma; 2008 Jan; 49(1):4-5. PubMed ID: 18203000
[No Abstract] [Full Text] [Related]
2. Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.
Venner CP; Gillmore JD; Sachchithanantham S; Mahmood S; Lane T; Foard D; Roussel M; Rannigan L; Gibbs SDj; Pinney JH; Whelan CJ; Lachmann HJ; Hawkins PN; Wechalekar AD
Haematologica; 2014 Dec; 99(12):e260-3. PubMed ID: 25193959
[No Abstract] [Full Text] [Related]
3. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report.
Gertz MA; Lacy MQ; Dispenzieri A; Hayman SR; Kumar SK; Dingli D; Ansell SM; Gastineau DA; Inwards DJ; Johnston PB; Litzow MR; Micallef IN; Porrata LF; Leung N; Hogan WJ; Buadi FK
Leuk Lymphoma; 2010 Dec; 51(12):2181-7. PubMed ID: 20958232
[TBL] [Abstract][Full Text] [Related]
4. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
5. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
Cordes S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kumar SK; Hogan WJ; Gertz MA
Cancer; 2012 Dec; 118(24):6105-9. PubMed ID: 22707405
[TBL] [Abstract][Full Text] [Related]
6. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.
Afrough A; Saliba RM; Hamdi A; El Fakih R; Varma A; Dinh YT; Rondon G; Cornelison AM; Shah ND; Bashir Q; Shah JJ; Hosing C; Popat U; Orlowski RZ; Champlin RE; Parmar S; Qazilbash MH
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1413-7. PubMed ID: 25842049
[TBL] [Abstract][Full Text] [Related]
7. Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival.
Tandon N; Muchtar E; Sidana S; Dispenzieri A; Lacy MQ; Dingli D; Buadi FK; Hayman SR; Chakraborty R; Hogan WJ; Gonsalves W; Warsame R; Kourelis TV; Leung N; Kapoor P; Kumar SK; Gertz MA
Bone Marrow Transplant; 2017 Aug; 52(8):1126-1132. PubMed ID: 28394369
[TBL] [Abstract][Full Text] [Related]
8. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.
Gertz M; Lacy M; Dispenzieri A; Hayman S; Kumar S; Buadi F; Leung N; Litzow M
Leuk Lymphoma; 2008 Jan; 49(1):36-41. PubMed ID: 18203009
[TBL] [Abstract][Full Text] [Related]
9. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.
Leung N; Kumar SK; Glavey SV; Dispenzieri A; Lacy MQ; Buadi FK; Hayman SR; Dingli D; Kapoor P; Zeldenrust SR; Russell SJ; Lust JA; Hogan WJ; Rajkumar SV; Gastineau DA; Kourelis TV; Lin Y; Gonsalves WI; Go RS; Gertz MA
Nephrol Dial Transplant; 2016 Aug; 31(8):1284-9. PubMed ID: 26627634
[TBL] [Abstract][Full Text] [Related]
10. Disease-free survival following high dose or standard dose therapy in patients with amyloidosis.
Kiel PJ; Trueg AO; Ferguson M; Benson M; Abonour R
Br J Haematol; 2016 Jul; 174(1):153-5. PubMed ID: 26314806
[No Abstract] [Full Text] [Related]
11. Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Sher T; Dispenzieri A; Gertz MA
Biol Blood Marrow Transplant; 2016 May; 22(5):796-801. PubMed ID: 26475727
[TBL] [Abstract][Full Text] [Related]
12. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review.
Mhaskar R; Kumar A; Behera M; Kharfan-Dabaja MA; Djulbegovic B
Biol Blood Marrow Transplant; 2009 Aug; 15(8):893-902. PubMed ID: 19589478
[TBL] [Abstract][Full Text] [Related]
13. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.
Vesole DH; Pérez WS; Akasheh M; Boudreau C; Reece DE; Bredeson CN;
Mayo Clin Proc; 2006 Jul; 81(7):880-8. PubMed ID: 16835967
[TBL] [Abstract][Full Text] [Related]
14. Re-examining the role of high-dose chemotherapy in the treatment of light chain amyloidosis.
Devine SM
Biol Blood Marrow Transplant; 2014 Jan; 20(1):14-9. PubMed ID: 24291621
[No Abstract] [Full Text] [Related]
15. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
16. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
[TBL] [Abstract][Full Text] [Related]
17. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
Sanchorawala V; Wright DG; Quillen K; Finn KT; Dember LM; Berk JL; Doros G; Fisher C; Skinner M; Seldin DC
Bone Marrow Transplant; 2007 Sep; 40(6):557-62. PubMed ID: 17589534
[TBL] [Abstract][Full Text] [Related]
18. Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.
Brunvand MW; Bitter M
Haematologica; 2010 Mar; 95(3):519-21. PubMed ID: 19903681
[No Abstract] [Full Text] [Related]
19. High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center.
Tsai SB; Seldin DC; Quillen K; Berk JL; Ruberg FL; Meier-Ewert H; Sloan JM; Doros G; Finn KT; Skinner M; Sanchorawala V
Blood; 2012 Nov; 120(22):4445-6. PubMed ID: 23175664
[No Abstract] [Full Text] [Related]
20. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.
Mollee PN; Wechalekar AD; Pereira DL; Franke N; Reece D; Chen C; Stewart AK
Bone Marrow Transplant; 2004 Feb; 33(3):271-7. PubMed ID: 14647248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
